Most treatment protocols result in a good outcome for TEL/AML1-positive ALL patients, but TEL/AML1 translocation is not currently used as a stratifying marker in most therapeutical protocols [2-5]. The gene discussed is RUNX1; the disease is acute lymphoblastic leukemia.